Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer and liver cancer. Provectus investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for psoriasis. In addition, Provectus has begun a Phase 3 trial as a therapy for metastatic melanoma. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
The red synthetic dye Rose Bengal is shown in a bottle at Provectus Pharmaceuticals, Inc.
This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices.
For Clinical Trials and Compassionate Use Programs ; Investor Information including SEC filing and Corporate Presentations; Press and Media REleases; and Contact information:
PVCT on YouTube...
CURRENT PVCT PIPELINE (as of May 23, 2017)
Current Real time Quote with links to Before and After Hours activity, Institutional Ownership and more:
Charts and Technical:
PVCT 6 months chart:
PVCT News and Analysis:
PVCT News Blogs with the latest news and analysis:
CONNECTING THE DOTS - CURRENT NEWS PAGE
CONNECTING THE DOTS - BLOG PAGE
PVCT News at OTC
CLINICAL TRIALS Updates and Info:
PVCT Share Structure
Market Value: $18,517,732 a/o May 04, 2017
Authorized Shares: 1,000,000,000 a/o Apr 30, 2017
Outstanding Shares: 370,354,643 a/o Apr 30, 2017
Held at DTC: N/A
Float: 75,807,312 a/o Jun 30, 2016
Par Value: 0.001
Shareholders of Record: 972 a/o Mar 31, 2017
Short Selling Data